2-(1-Methyl-1h-benzoimidazol-2-yl)-ethylamine dihydrochloride | 138078-14-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2-(1-Methyl-1h-benzoimidazol-2-yl)-ethylamine dihydrochloride
• 英文别名: 2-(1-methylbenzimidazol-2-yl)ethanamine;dihydrochloride
• CAS: 138078-14-5
• 化学式: C10H15Cl2N3
• mdl: MFCD03840416
• 分子量: 248.15
• InChiKey: PZRXJCCZWOQMOU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.92
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  43.8
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-methyl-1H-imidazole-4,5-dicarboxylic acid 4-methyl ester 、 2-(1-Methyl-1h-benzoimidazol-2-yl)-ethylamine dihydrochloride 、 生成 1-methyl-5-(2-(1-methyl-1H-benzo[d]imidazol-2-yl)ethylcarbamoyl)-1H-imidazole-4-carboxylic acid methyl ester
  参考文献：
  名称：

  PDE10 modulators

  摘要：

  本发明涉及式(I)化合物，其中R1、R2、R3、R5、W、X、X1、Y、Y1、Z和Z1如说明书和权利要求所定义，并且其生理学上可接受的盐。这些化合物抑制PDE10A，可用于治疗中枢神经系统疾病，如精神分裂症、阿尔茨海默病和帕金森病。

  公开号：

  US08772510B2

文献信息

• [EN] NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A<br/>[FR] NOUVEAUX COMPOSÉS INHIBITEURS DE LA PHOSPHODIESTÉRASE DE TYPE 10A
  申请人：ABBVIE DEUTSCHLAND

  公开号：WO2014140184A1

  公开（公告）日：2014-09-18

  The present invention relates to compounds of the formula (I), the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof. In formula I the variables Het, A, X, Y, Z, R1, R2, R3, R4, R5 and Q are as defined in the claims. The compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type 10A. Thus, the invention also relates to the use of the compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.

  本发明涉及通式(I)的化合物、其N-氧化物、互变异构体、前药及其药学上可接受的盐。在式I中，变量Het、A、X、Y、Z、R1、R2、R3、R4、R5和Q如权利要求中所定义。通式I的化合物、其N-氧化物、互变异构体、前药及其药学上可接受的盐是磷酸二酯酶10A的抑制剂。因此，本发明还涉及通式I的化合物、其N-氧化物、互变异构体、前药及其药学上可接受的盐用于制备药物的用途，这些药物适用于治疗或控制选自神经性疾病和精神性疾病的医疗病症，以改善与这些病症相关的症状，并降低这些病症的风险。
• PDE10 MODULATORS
  申请人：Bachmann Stephan

  公开号：US20130059833A1

  公开（公告）日：2013-03-07

  The present invention relates to compounds of formula (I) wherein R 1 , R 2 , R 3 , R 5 , W, X, X 1 , Y, Y 1 , Z and Z 1 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit PDE10A and can be used in the treatment of CNS disorders such as schizophrenia, Alzheimer's disease, and Parkinson's disease.

  本发明涉及式(I)的化合物，其中R1、R2、R3、R5、W、X、X1、Y、Y1、Z和Z1如描述和权利要求中定义，并且其生理上可接受的盐。这些化合物抑制PDE10A，可用于治疗中枢神经系统疾病，如精神分裂症、阿尔茨海默病和帕金森病。
• [EN] PDE10 MODULATORS<br/>[FR] MODULATEURS DE PDE10
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013034506A1

  公开（公告）日：2013-03-14

  The present invention relates to compounds of formula (I) wherein R1, R2, R3, R5, W, X, X1, Y, Y1, Z and Z1 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit PDE10A and can be used as medicaments.

  本发明涉及以下式（I）的化合物，其中R1、R2、R3、R5、W、X、X1、Y、Y1、Z和Z1如描述和权利要求中所定义，并且其生理学上可接受的盐。这些化合物抑制PDE10A，可用作药物。
• NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A
  申请人：AbbVie Inc.

  公开号：US20140303153A1

  公开（公告）日：2014-10-09

  The present invention relates to compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof: In formula I the variables Het, A, X, Y, Z, R1, R2, R3, R4, R5 and Q are as defined in the claims. The compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type 10A. Thus, the invention also relates to the use of the compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.

  本发明涉及公式I的化合物，其N-氧化物，互变异构体，前药和药学上可接受的盐：在公式I中，变量Het、A、X、Y、Z、R1、R2、R3、R4、R5和Q的定义如权利要求书所述。公式I的化合物，N-氧化物，互变异构体，前药和药学上可接受的盐是磷酸二酯酶10A的抑制剂。因此，本发明还涉及使用公式I的化合物，N-氧化物，互变异构体，前药和药学上可接受的盐制造药物，因此适用于治疗或控制神经系统和精神障碍，改善与此类障碍相关的症状并降低此类障碍的风险。
• Inhibitor compounds of phosphodiesterase type 10A
  申请人：AbbVie Deutschland GmbH & Co. KG

  公开号：US09163019B2

  公开（公告）日：2015-10-20

  The present invention relates to compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof: In formula I the variables Het, A, X, Y, Z, R1, R2, R3, R4, R5 and Q are as defined in the claims. The compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type 10A. Thus, the invention also relates to the use of the compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.

  本发明涉及公式I的化合物，其N-氧化物，互变异构体，前药和药学上可接受的盐：在公式I中，变量Het，A，X，Y，Z，R1，R2，R3，R4，R5和Q的定义如所述。公式I的化合物，其N-氧化物，互变异构体，前药和药学上可接受的盐是磷酸二酯酶10A的抑制剂。因此，本发明还涉及使用公式I的化合物，其N-氧化物，互变异构体，前药和药学上可接受的盐制造药物，适用于治疗或控制神经系统和精神障碍，改善与此类障碍相关的症状，降低此类障碍的风险。